Latest news
25 items- PRSema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope
- INSIDERSEC Form 4 filed by Sherman Rachel E.4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Turner Nat4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Pellini Michael J4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Ruch Joshua4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Ryan Jason4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Leproust Emily M.4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Casdin Eli4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Charney Dennis4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- SECSEC Form 424B3 filed by CM Life Sciences, Inc.424B3 - Sema4 Holdings Corp. (0001818331) (Filer)
- SECCM Life Sciences, Inc. filed SEC Form 8-K: Leadership Update8-K - Sema4 Holdings Corp. (0001818331) (Filer)
- 13D/GSEC Form SC 13D filed by CM Life Sciences, Inc.SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)
- INSIDERSEC Form 3: New insider Icahn School Of Medicine At Mount Sinai claimed ownership of 88,355,473 shares3 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Assad Shawn4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Assad Shawn4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by White Karen Ann4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Saad Kareem4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Coffin James4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Ro Isaac4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Schadt Eric4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Clark Daniel Emmett4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- INSIDERSEC Form 4 filed by Prentice Anthony4 - Sema4 Holdings Corp. (0001818331) (Issuer)
- SECSEC Form S-8 filed by CM Life Sciences, Inc.S-8 - Sema4 Holdings Corp. (0001818331) (Filer)
- 13D/GSEC Form SC 13D filed by CM Life Sciences, Inc.SC 13D - Sema4 Holdings Corp. (0001818331) (Subject)
- INSIDERSEC Form 3: New insider Blackstone Tactical Opportunities Fund - Fd L.P. claimed ownership of 25,156,993 units of Class A Common Stock3 - Sema4 Holdings Corp. (0001818331) (Issuer)
CMLF FAQ
5 questionsWhere does CMLF stock trade?
CM Life Sciences, Inc. (CMLF) is listed on NASDAQ.What sector and industry is CMLF in?
CM Life Sciences, Inc. operates in the Finance sector, Business Services industry.When did CM Life Sciences, Inc. go public?
CM Life Sciences, Inc. (CMLF) completed its IPO in 2020.What companies are similar to CMLF?
Notable peers in the same industry include FLT (FleetCor Technologies Inc.), NVEI (Nuvei Corporation Subordinate Voting Shares), NLSN (Nielsen N.V.), STMP (Stamps.com Inc.), ENV (Envestnet Inc). Compare CMLF side-by-side with any of them on Quantisnow.How can I track CMLF on Quantisnow?
Quantisnow aggregates CM Life Sciences, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CMLF to receive live email and push alerts on every new disclosure.